Frontlight ResearchEarly access
TerminatedPhase 3
Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 323 people enrolled
- Started
- 8 Jul 2021
- Ended
- 10 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Clorazepate Dipotassium
- Placebo
- Ketoprofen
- Metoclopramide
- Record updated
- 8 September 2025
- Why it stopped
- It has been determined that continuing with enrollments in this study is no longer justified due to the lack of significant impact on the expected outcomes.
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age from 18 to 70
- Patient suffering migraine or probable migraine (diagnosis made by neurologist according to IHCD3)
- Present migraine attack lasting ≤ 72 hours
- Headache intensity moderate or severe on the verbal ordinal scale (4 levels: no headache, mild, moderate or severe)
- Patient requiring parenteral treatment
- Affiliation to the French Health-care System "sécurité sociale"
Who cannot take part
- Patient requiering treatment with sumatriptan SC, particularly in the event of failure of an anti-inflammatory drug at an effective dose taken within 6 hours
- contraindication to any of the investigational medication
- previous participation to this study
- abnormalities of neurological exam, seizure, fever (≥ 38°C), and/or SBP≥180 and/or DBP≥110 mmHg
- known respiratory or liver insufficiency
- suspicion of secondary headache
- inability to understand the consent or scales
- pregnancy or breast-feeding
- acute alcohol consumption or alcoholism
- myasthenia
- recent use of benzodiazepines (< 24h diazepam, clonazepam, clorazepate ; < 6h alprazolam, lorazepam, midazolam)
- recent use of pain killers (< 2h)
- contraindication to intravenous access
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy of clorazepate in addition to the usual medication for treating migraine attack in the emergency room
The 2 groups in the trial
- Control armPlacebo, for comparison
placebo and standard care : * Placebo IV * Ketoprofen 100 mg IV (if nausea-vomiting) * Metoclopramide 10 mg IV(if nausea-vomiting)
Treatment: Placebo, Ketoprofen, and Metoclopramide
- Experimental armTreatment being tested
clorazepate and standard care : * Clorazepate 20 mg IV * Ketoprofen 100 mg IV (if nausea-vomiting) * Metoclopramide 10 mg IV(if nausea-vomiting)
Treatment: Clorazepate Dipotassium, Ketoprofen, and Metoclopramide
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
- Record updated
- 8 September 2025